HAIRY CELL LEUKEMIA VARIANT
Clinical trials for HAIRY CELL LEUKEMIA VARIANT explained in plain language.
Never miss a new study
Get alerted when new HAIRY CELL LEUKEMIA VARIANT trials appear
Sign up with your email to follow new studies for HAIRY CELL LEUKEMIA VARIANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets rare blood cancer in early trial
Disease control OngoingThis early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …
Matched conditions: HAIRY CELL LEUKEMIA VARIANT
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Targeted drug ibrutinib shows promise against rare leukemia
Disease control OngoingThis phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.
Matched conditions: HAIRY CELL LEUKEMIA VARIANT
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC